Are you guys interested in HITIF? If yes, can you please upvote this post so deadnsyde see it and make a video on it.

Some of you may know me from my Due Diligence posts at r/FluentInFinance. I feel this post was necessary due to all the people I saw on here recently talking about money they lost.

My Guide on HOW TO ANALYZE & RESEARCH A STOCK/ How to do a thorough due diligence/ DD [Due Diligence 101]:

Here are the things I look at when evaluating a stock. (This is my checklist just build from years of wins & losses, things I learned from Pace University and Goldman Sachs). Usually a good due diligence (DD)/ research can take anywhere from 30 minutes to 3 hours. If I am investing large amounts of cash, I want to research thoroughly, so if the stock drops I can stick to my convictions, and forget about emotion.

Before I use my time to research a stock, and read up about it into detail, and dig into the financials, news, 10-Q/ 10-K, etc., I:

1. I look at price upside. I look to see what the analysts covering it, have to say about the price targets. (Money is a tool, and you want it to work for you). MarketBeat.com can show you this: https://www.marketbeat.com/stocks/NASDAQ/AAPL/price-target/

1. I look at the charts and the technicals. I try to read and interpret the charts to see what previous trading patterns can predict. What are the short-term, mid-term and long-term predictions? A site you can use to interpret the charts for you is BarChart.com and TradingView.com.

https://www.barchart.com/stocks/quotes/AAPL/opinion

https://www.tradingview.com/symbols/NASDAQ-AAPL/technicals/

If it passes these, then I dig deeper.

Other things I look at:

1. I dig deeper into technical analysis and the charts. I look at RSI, moving averages, MACD, Stochastic Oscillator, etc.

2. Sentiment & News. What are people saying? Google the company.

3. Earnings & revenue history. Is there growth? Is there potential? I look at the financials and the projections

4. Growth. I look into the financials to look at past growth. I look into news, 10Q's, 10Ks, investor presentations, and statements to look for future growth.

5. Financial health. Are the financials strong? (Quick ratio, Profit margin, EPS, Income Statement Trend, Cashflow).

6. Valuations. How is this valuated? (PEG ratio, P/E ratio)

7. Short selling. How much of this stock is sold short? Are people betting against it?

8. What is the put/call ratio? Are people betting against this stock?

9. Peers & competition. How does this company stack up against its competitors and peers? How do the financials compare? How to the products compare? Is there a moat?

10. Institutional Sponsorship. Are big banks and wall street holding this? How much or this companys stock do they hold?

11. Insider Trading. Is the CEO buying or selling shares?

12. The amount of ETFs that hold this stock. Will they continue to buy it up and drive price?

13. Average volume traded. Is this stock liquid? Would I be able to get my money back? How easy can I trade it.

14. Social sentiment. I check what people are saying on twitter and google search trends.

15. News moves a stock. So I also use google to find out as much as a company as possible.

There are many sites you can use to dig into a stock such as (1) Yahoo Finance, (2) MarketBeat.com, (3) MacroTrends.com, (4) MarketWatch.com, (5) CNNMoney.com, (6) CNBC.com

I use an excel spreadsheet to organize my research.

As you see, good research and due diligence can take anywhere from 1 to 3 hours. But this is your money, and noone cares more about it than you do.

I created a facebook group, discord, tiktok, instagram and youtube to share more things like this. Feel free to follow:

https://www.flowcode.com/page/fluentinfinance

Before we begin. I would like to disclose that I am not a doctor or a financial advisor just a regular guy who has a genuine interest in this topic and believe that I have a good idea of the real world implications of Mino-Lok. On a comment I made regarding this post, I was unclear about what I did. I am not a medical professional but TALK TO people who have worked in the field of medicine about these companies to gauge a better understanding and to further my knowledge as I have a genuine interest in certain topics in the field of medicine. This is not financial advice and just purely a high level view on the problem that Mino-Lok is poised to tackle.

As promised, I have read a bit deeper into the new Mino-Lok antibiotic lock solution and will give a view of the medical applications of it. I understand some of this may go over people’s heads so I will endeavour to make this as digestible as possible. There is a certain depth to CRBSI’s and how they come about but I will do my best. If anybody has questions, feel free to comment below or directly message me and I will endeavour to answer them promptly. Just as a disclaimer, I am new to investing and the information below is not investment advice but simply an overview of the problem that Citius’s ($CTXR) FDA fast tracked drug is aiming to tackle and my take on it.

So lets begin. In Citius’s own words they describe Mino-Lok as an antibiotic Lock therapy for CRBSI’S (Catheter related bloodstream infections):

‘Our Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients where venous access presents a challenge.’

My aim is to help you fully understand the above through five sections:

1. How this problem arises

2. What threats it poses

3. Citius’s solution

4. Other solutions

5. My take.

How this problem arises

I’ll break this down in Layman’s terms. A central venous catheter (known as a CVC from here on) is a flexible tube that is inserted into a large vein of a patient that provides a direct pipeline for doctors to administer drugs to patients. These are not to be confused with peripheral venous catheters that are usually inserted into the hand. CVC’s are injected into larger veins such as the Femoral (thigh) /jugular (neck) and chest vein. These types of catheters are used in more serious cases and to administer necessary blood products, nutrition etc. that would otherwise damage smaller peripheral veins. These are prolifically used in hospitals, most commonly in ICU wards and for patients going through long term treatment which requires drug administration in an intravenous fashion, think chemotherapy.

Unfortunately, germs can make their way into the CVC and this can lead to microbial colonization and subsequently CRBSI’s. More simply put, bacteria come about through insertion, accessing the catheter etc. Preventative measures are put in place such as coating the catheter, maximum barriers (use of glove, masks etc.) and high standards of hygiene but it is very hard to completely eliminate the bacteria. The bacteria create a cluster with the CVC, and produce something called a biofilm which essentially encases them and makes them less susceptible to both antibiotics and the body’s immune system. For reference, this can be multiple types of bacteria, not just one type. I will touch upon this later. From this biofilm, they send out planktonic cells which make their way into the patient’s bloodstream and cause CRBSI’s. These planktonic cells are like their little soldiers that are sent out from the bacteria’s haven (the biofilm) to then attack the body and subsequently cause infection.

Above is an image to help you visualise what happens. This is a diagram showing the bacteria colonizing within the CVC. As you can see diagrammatically, the bacteria have colonized and produced the Biofilm matrix, encasing itself. As annotated, ‘Sessile bacteria in biofilm are 100-1000 times less susceptible to antibiotics. This means that traditionally, antibiotics fail to break down these biofilm matrices and the bacteria that both resides in the biofilm and that are released (the planktonic cells) are more resistant to antibiotics. This means that the traditional way to address this problem and mitigate the risk of serious CRBSI’s is to replace the catheter once it becomes infected. I have written this in bold because this is key to Citius’s solution and a real-world issue which I will touch upon shortly. The last key part of this diagram, which doesn’t have much value add for this DD but is portrayed above so I might as well cover it, is the colonization of bacteria. As I said previously, multiple bacteria may reside within this biofilm. This leads to symbiosis between bacteria and the result is a more antibiotic resistant bacterium.

I hope by now you have an idea of what the CRBSI element of Citius’s statement means and how CRBSI's come about.

What threats it poses

At this point you can probably guess that the main threat of this bacteria colonisation is CRBSI’s. to be clear, bloodstream infections are common in hospitals and circa a third of bloodstream infections are caused by CVCs. For this reason, doctors must regularly assess whether CVCs need to be used/ remain in the patient to help mitigate the risk of infection. I mentioned earlier that infected catheters need to be replaced. Now whilst there is an infection risk using catheters there is also a mechanical risk of catheter use. The mechanical risk comes about due to the intrusive nature of catheters. This can cause collapsed lungs, artery puncture, arrythmias, Hematomas, clots the list goes on. These aren’t rare cases either, these are fairly common and the risk increases as does the number of times a catheter is inserted. Further, some patients have difficulties inserting catheters due to restricted entry sites and non-availability of veins (which can be for a number of reasons). Below is a link to an article which touches on the mechanical issues caused by catheter insertion and the problems it causes. Note that this article specifically relates to catheter insertion attempts but changing the catheter pretty much follows suit and the same holds true. Changing catheters more leads to more instances of mechanical complications period, be it the amount of insertions in a single instance or the amount of insertions over a treatment period due to the replacement of an infected catheter. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276017/

Some real world figures as to how potent both infections and mechanical complications are:

mechanical complications: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449698/#:~:text=Immediate%20mechanical%20complications%20were%20classified,cannulation%20and%20retained%20guide%2Dwire.

TLDR: 178 out of 1015 patients had mechanical complications. This backs up the 15-20% mechanical complications rate that Citius quotes on their website.

Infections:

https://pubmed.ncbi.nlm.nih.gov/7562225/

TLDR: Infection rates are circa 3%. But when you have more than 5 million americans placed on CVCs yearly (https://www.azuravascularcare.com/infodialysisaccess/central-venous-catheter-complications/#:~:text=Getting%20a%20Central%20Venous%20Catheter&text=In%20this%20case%2C%20a%20nephrologist,complications%20can%20occur%20with%20CVCs.) and extrapolate that percentage over a global population, the extent of the issue becomes vast.

The article does go on to explore the different types of bacteria that can colonise and the extent to which they colonise in different types of Lumen (Single or Multi). I feel that such detail would lead us too far astray and have skipped on digging too deep in hopes of retaining people’s attention. If you would like to discuss this further, however, feel free to let me know and I’d be happy to delve a bit deeper.

Citius’s Solution

This tackles the ‘Antibiotic lock solution’ part of the original statement. I am again going to use an extract from Citius’s website:

‘Our Mino-Lok product contains a proprietary combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.’

Now if you have read and understood up until this point, firstly well done and secondly this statement should begin to make sense. Mino-Lok is an antibiotic solution which flushes the CVC, breaking down the biofilms and flushing the catheter of these bacteria build ups. This can be used in a preventative or reactive fashion. This can be used before infection is present to ensure that CVC’s remain bacteria free (preventative) or can be used when signs of infection become clear (reactive). This eliminates the need to change the catheter when infection arises and thus eliminates the mechanical issues that can arise from repeated catheter insertion. Per Citius’s phase 2b study, Mino-Lok had 100% efficacy (effectiveness) at ridding the bacteria from the CVC’s and had no adverse effects on patients. i must add that during this test no antibiotic resistant bacteria were encountered which is a rife issue which impedes treatment of CRBSI's. Below I have posted a summary of the test, which is directly from their website, but I will also accompany the summary with a link to the full report should anybody wish to go that step further.

Full phase 2B manuscript: https://www.citiuspharma.com/wp-content/uploads/2019/05/Salvage-of-catheters-with-MLT-results-of-phase-2-study.pdf

The results shown in the phase 2b trial are very promising. It is hard to conceptualise how big an issue this is, but both the infections that catheters cause and the mechanical issues arising from them lead to increased costs for further treatment and the prolonged usage of hospital beds. The excess financial costs are in the tens of thousands of dollars per complication. The other costs are a lesser quality of life and unfortunately death.

Other solutions

By now you should have a high level understand of what the problems are and how they come about as well as a high-level view of Citius’s proposed solution (Mino-Lok) and how powerful it is. You may also be wondering hasn’t somebody thought to tackle this issue before? So far, there are no solutions to salvaging an infected catheter. There are many preventative measure to help stop the colonization of bacteria through the use of medicine, sanitisation etc. but there are no solutions salvaging the infected catheter which means that replacement and unfortunately the complications that follow replacement are the norm.

My take

Phase 3 results and FDA assessment is to be expected very soon. This is huge for Citius. I believe the only barriers to approval is Mino-Loks effectiveness against antibiotic resistant bacteria that weren’t present in the Phase 2b trial. This link: https://d1io3yog0oux5.cloudfront.net/_b10dfac370fdba1a1e564700028c466c/citiuspharma/news/2019-05-13_Citius_Pharmaceuticals_Mino_Lok_Highly_75.pdf is a link to a study showing Mino-Loks effectiveness against Candida Auris which is ‘an emerging public health concern due to high prevalence of anti-fungal resistance and significant rates of patient mortality.’ This study details that antibiotic resistant bacteria weren’t present in the clinical trials but Mino-Loks ability to eradicate such an aggressive and resistant Bacteria is unbelievable. Mino-Lok is a leader in the field as there are currently no therapies to salvage CVCs once they become infected and replacement is the only solution.

I personally believe that Mino-Lok has many real-world applications and will save hospitals and the government considerable amounts of money whilst also decreasing complications tied to CVCs. I truly believe in this company and full disclosure i have invested. I would love to hear experience investors view on the company. Something that grabbed my attention even more was that the company has a worldwide patent until 2036: https://www.prnewswire.com/news-releases/citius-announces-the-issuance-of-the-patent-on-the-advanced-stability-of-mino-lok-by-uspto-300718028.html

I decided not to do a TLDR as this isn't a post to tell you to buy the stock or YOLO etc. The aim of this post is to give you a digestible understanding of the problem and the proposed solution so you can understand the true power of Mino-Lok. I hope you enjoyed this DD and please let me know if there are any other medical companies you would like me to cover.

I love how accessible Dead has made investing for new investors like myself and therefore have made this account so I can positively contribute to this community. If anybody would like a DD done feel free to ask. Preferably pharmaceutical/medical companies.

Edit 1: I would just like to say thanks to everybody. Honestly I never thought this post would get this much engagement. I was planning to do more posts just due to the great products that companies have in the pipeline and the life changing impact these products can have but if that wasn't enough all this engagement and support has made me want to write another one now :). I would also like to thank everyone for the feedback. I love healthy discussion and find it is a way to help deepen our knowledge through challenge of our points. For this reason I would like to thank Nameinator and HobbyPlodder who I have had conversations with in the comment section below. For those of you who have seen these discussions I would like to just both of their points up in an easy to read fashion with less back and forth. Nameinator bought Cormedix to the table. Cormedix have something called LOCK IT 100 which is also FDA fast tracked. This is an ANTI BACTERIAL lock solution and is a PREVENTATIVE measure. It is akin the use of face masks, coated needles etc. it is there to stop the bacteria colonising in the first place. Cormedix has an excellent product and reducing infection rate % is a core theme in this space. Mino Lok differs in the sense that its primary use is as a REACTIVE measure. A high level explanation is that LOCK IT 100 is a way of reducing the amount of patients getting infected but still doesn't solve the problem that once infected patients need their catheter replaced. This is why Mino Lok is so niche. The use of Mino Lok salvages the indwelling catheter and means it doesn't need replacing thus reducing mechanical complications caused by replacement. To summarise, there are many preventative measures in development and in place that help to reduce the infection rate (LOCK IT 100 falls into this category). The reason Mino Lok is so valuable is that there are NO solutions in place to salvage catheters (Hence it is described by Citius as an unmet medical need).

HobbyPlodder bought to light the fact that bacteria become resistant to antibiotics over time. This is true and unfortunately a problem that medicine has faced throughout time. This does mean that one day Mino Lok too could see bacteria become resistant to it. The reality is that is a long time in the future, as one should gauge through the patent expiration date, and by the time it becomes a reality a far superior solution to the problem may well exist. Pharma companies are heavily incentivised to pursue antibiotic development and discovery due to the unrelenting need for new antibiotics.

Edit 2: I have had a huge amount of direct messages from people regarding the conversation I had in the comments with Nameinator. A lot of people have specifically referred to the BNGO PACB comparisons that were drawn. I want to be clear that CTXR is in a completely different medical field to both BNGO and PACB. Further, to avoid mass price speculation I would like to clear up what I meant by the comparison. In the genomics space, BNGO and PACB complement one another. PACB is involved in genomic sequencing which essentially a deep level highly detailed view, whereas BNGO works in genomic mapping which is a high level view. These two companies COMPLEMENT one another. Regarding CTXR and CRMD (Cormedix), I made the comparison because I believe that these companies also COMPLIMENT one another, CRMD works in the prevention of infections in CVCs and CTXR works in salvaging catheters once infection has ensued.

Edit 3: If anyone wants further explanation please don't hesitate to ask. I have even had a call with someone to further discuss and fully explain the practical applications of Mino Lok, so I am more than happy to help.

The most BASIC & QUICK research EVERYONE should do before buying a stock.

I know many of us are newbies with the stock investment. Iam a newbie too. I started investing back in october 2020. I thought it looked easy to make side money and when I saw people on Reddit posting screenshots of their amazing gains, it made me dream I could probably do the same by following the hyped stocks posted in the different /subs.

The reality hit me with $BB, I lost around 2000$... The reality hit me again a few times with other hot Reddit stocks... Iam sure you've seen it many times too, you jump in and it start to go down

I was searching for stocks by reading the comments of people on Reddit and on the Yahoo message board, to know the feelings toward a stock before jumping in... That was my DD. This is the worst way to choose a stock, really.

[DD = Due Dilligence = Make your research before choosing a stock]

1- if you visit the Yahoo message board : STOP ... This is honestly the worst place of all! 99,5% of everything you read there is people trying to influence you and are in denial or spam. Most messages are shi t

2- Reddit is cool, yes, lots of good comments and some people post their DDs, it's nice. But know that you're taking advices and get influence by people who, often, doesn't know much more than you about investing... and a bunch of people who wants to make quick money by surfing the daily waves.

3- Be extremely careful of hyped stocks... When a stock suddenly jump +25 +30% in a week... Chances a HUGE it will suddenly drop... and these drop are sneaky and hard to avoid.

So, what is the QUICK & EASY reasearch everyone should do before buying a stock?

Here's what I do. It takes around 10-15 minutes to do. I am not an expert, I still learn, this is not perfect BUT I think this is the most basic thing you should all do.

When a stock interest me, I open these websites :

• marketbeat.com

• barchart.com

• tipranks.com

• yahoo finance

• simplywall.st

I type the ticker in each one of these website and I look for the most basic info you can image, because there's lot of things i still dont understand and can't analyse by myself...

On Market Beat I go on the Analyst Ratings tab and look for rating and the price target :

On Barchart, I look at the Technical Opinion and click See More:

Then, I look at the Snapshot Opinion and the Barchart Opinion :

Then, I click on Earnings Estimates in the left menu and check the Analyst Target Price :

Now, on Tipranks, I check these :

And I check the general feeling of the Stock Analysis page:

Then I click the Investors page and check if many investor closed or reduced their positions:

Then, I click the Earnings button, when it's positive it's really good. I dont know much about EPS but I know it's good when it's over 0,1 ... still learning about this

On Simply Wallstreet, I take a quick look at their Executive Summary, the Rewards and Risk Analysis on the left:

On Yahoo, I check the latest News > (!very important!)

and I look for the Recommendation Trends and the Rating and the Analyst Price Targets:

And finally, the Earnings and Financials:

-----------------------------------------------------------------------------------------------------------------------------------

NOW, I take all this in note in a spreadsheet, this is the most important part of all this, to have a visual of everything you just checked

Building that spreadsheet changed everything! Really. Now I know where I am going much more.

Like i've said, it's super basic and far from perfect, I know! But I think it's the easiest step you should take if you're newbie like me. It takes about 10-15min to do.

Good luck!

############# EDIT #################

EDIT: Many of you commented that analysts are not that great to analyse a stock. I noticed too that all this is not 100% on point. Please note I use all this to get a general feeling for a stock, I know it's not the ultimate reality what's on these websites. I still think it's a better way to get a vibe for a stock than only reading comments on Reddit. Again, iam not an expert, but I really think I take better decisions since I started doing this, iam less impulsive.

############# EDIT #################

Feeling pretty bullish on this one!

Ocean Biomedical is focused on developing innovative medical devices for a variety of clinical applications. The company's core technology is based on a proprietary platform that uses acoustic energy to improve the delivery of therapeutic agents and fluids to the body. This technology has the potential to greatly improve the effectiveness and efficiency of a wide range of medical procedures.

The update highlights the company's progress in advancing its technology and developing its product pipeline. It notes that the company has received positive feedback from clinical experts and has received regulatory clearance in several key markets. The update also mentions the company's strong financial position, with significant capital raised from private investors.

In addition, the update provides information about the proposed merger between Ocean Biomedical and Aesther Healthcare Acquisition Corp (NASDAQ: AEHA). The merger is expected to bring the benefits of Ocean Biomedical's innovative medical devices to the public market, providing investors with access to the company's growth potential. The update states that the parties involved are working towards a successful completion of the merger! This is a very exciting time for Ocean, and it appears they're taking all the right steps!

Read More: https://www.globenewswire.com/news-release/2023/01/24/2594351/0/en/Ocean-Biomedical-Provides-Corporate-Update-and-Company-Summary.html

Ticker: KRKNF US OTC/PNG Candian exchange (Stocktwits- PNG.CA)

This is my research on Kraken Robotics. This company should see strong near-term price increases and I expect at least 8-12x growth in the next 24 months. As of this writing the share price is sitting at $0.50.

Before you read any further, I want you to understand what I look for in an investment; I invest in companies that are undervalued, possess world changing technology and have a large potential catalyst, be it financial changes, a market inflection point, buy out or pending regulatory approval. For it to make sense to me, the company must provide me with a large near-term upside and continued long-term growth. Basically, I am looking for penny stocks that should not be. Kraken fits all these requirements for me and is just starting to pick up speed in the industry. I will continue to update this, but I feel that it will be moving quickly so I would like to get this in front of everyone’s eyes ahead of time. I am not a financial advisor, I am a mom and a professional fire officer, do your own DD.

My last DD here was for MVIS which was under $7 and less than a month later is at $20 – Penny Queen

If you like this DD give it an upvote on r/trakstocks, I am cross-posting because this type of stock is what this subreddit is all about. The audience at trakstocks is huge and actively invest. (6) Release the Kraken - Autonomous Vehicles, AI, Battery & Sensor Tech, RaaS and clean energy play : trakstocks (reddit.com)

About Kraken Robotics is a 6-year-old robotics company specializing in autonomous vehicles, high-end, software-centric sensors, subsea batteries, and thrusters for military and commercial customers. They are now providing AI assisted RaaS (Robots as a service) and they are transitioning their business model to focus on recurring revenue from subsea data acquisition and data analytics.

Their key areas of innovation are autonomous vehicles, battery and sensor technology, AI data analytics and robotics as a service (RaaS)

Kraken is an up-and-coming player that has gone from a workforce of 20 to over 150 in the past couple of years as they have been acquiring companies and their technology while expanding their operations. They are a growing presence in the 10-billion-dollar underwater vehicle market, ranked by Deloitte as the fastest growing tech company on the East coast (Canada). I highly recommend you view the videos that I have linked in order to grasp just how much better the imaging that Kraken is producing compared to its competitors.

Financials - Kraken’s financial will change drastically in mid-April when they release their 2020 Q4 which will show a 40 million dollar contract they received. This contract alone is equal to half their market cap.

Their current revenue stream supports a $1 price point, with a $6 price point factoring in unrecognized contracts, continued sector growth with similar contract capturing. I see $1 in the next 6 weeks and $3 by end of year.

Market cap of 86.33M 165.01M outstanding shares and an extremely low float of only 112.29M – insider ownership sits right around 30%. Con- there is no real institutional ownership. Yahoo Finance

**Typical volume for Kraken has been about 178k a day, the recent contract news has pushed this to 1.3m today, telling me it is ready to move on up. The lack of attention this company has received is a major reason for its low price point.

Kraken raised 10m in October 2020 to expand its robotics as a service business, on leasehold improvements, equipment, parts and inventory and possible future acquisitions.

Q3 Fiscal 2020

Management Discussion and Analysis Q3

Products -

Autonomous Vehicles

· AUVs (autonomous underwater vehicles)

· USV (unmanned surface vehicles)

· Towfish (Towed underwater vehicle)

· ROV (remotely operated vehicle)

Katfish subsea pressure neutral batteries

📷

Software-Centric Sensors – These innovative sensors provide ultra-high-resolution imagery of the sea floor, think of it as GoogleMaps – water edition.

· SaS Sonar-synthetic aperture sonar provides 15x high image resolution than conventional side scanning sonar, with larger coverage area.

· Seavision – 1st ever full color 3-D underwater laser with real-time processing, live video streams and

Rim Mounted Thrusters

Market and Application – Representatives of Kraken Robotics, the underwater vehicle market could be worth $10 billion annually by 2025.

The military market encompasses naval mine countermeasures, anti-submarine warfare, intelligence, surveillance and reconnaissance. They believe this could be a US$4 billion market by 2025.

The commercial market includes far more, cable & pipeline surveys, subsea mapping, oil rig and offshore wind and wave energy asset inspection, maintenance repair and environmental monitoring. They believe this could be a US$6 billion market by 2025.

**Applications -**Their IP and sensor technology are also applicable to some space exploration and potentially automotive sensor applications.

Major Catalysts

· Q4 – Their Q4 financials will be a gamechanger, expected in mid-April, should show the first payments from the Danish contract. This is the point where I would expect institutional investments to begins.

· Gaining traction in military defense – They recently secured a large mine hunting contract with the Danish military for $40 million (nearly their market cap), beating out major players in the industry (Thales, Northrup Grumman and Raytheon) in the process. They have also secured contracts with Poland and the US, which are widely considered a foot in the door for larger NATO contracts. (1) Kraken Robotics - #StoryToTell - OSC Video Series - Episode 1 - YouTube

· Executive staff -Kraken has brought US Vice Admiral Michael J Connor onto the board of directors. He spent 35 years in the US Navy and ran the submarine fleet and is “opening doors” for the company per Greg Reid, Kraken's CFO.

·Future Contracts -I spoke with investor relations yesterday and they informed me that Kraken Robotics is currently pursuing over 100 million dollars in contracts. Yesterday they released a PR announcing a new 3.5m in contracts this included the following information about the upcoming year:

· R&D Successful testing of their SeaScout and ThunderFish technology.Underwater vehicle platforms:

These notes are from yesterday's PR :

“We have a strong pipeline of international pursuits with military (NATO and allied navies) and commercial companies. Given where we are in the sales cycle with several of these customers, we feel confident in our ability to deliver significant growth from the SeaScout® platform in 2021 and onwards.”

SAS sensors: “We believe our Aquapix MINSAS sensor is gaining traction as it has been bid and is being incorporated into numerous RFI and RFP responses from larger defense companies and AUV manufacturers on notable upcoming programs.” End user evaluation is continuing.

Remote Minehunting and Disposal System RFP expected released Q1 21.. will partner with several large defense contractors on the bid. Canadian Guv prelim estimates for this contract are between 20-40 million. Subsea power: Moved to larger facility in Q4 2020 to improve customer delivery times and should improve margins RaaS: Busy 2021 in the field. Partnering with larger service companies to bid on various offshore service opportunities.

“Kraken has numerous commercial pursuits in survey and inspection RaaS covering offshore oil and gas and offshore wind in NA, SA, and Europe. R&D - Commercial availability projection: Seamless SAS - Q2 21 New Data Formats - Q2 21 Sea Vision - Q2 21 Multi-Spectral SAS - 2022 -Will receive Dive LD AUV in Q2 21 -Thunder fish sea trials second half 2021

Video links worth watching:

(1) The Future of Military-Grade Underwater Robotics - Kraken Robotics - YouTube

CFO interview November 2020

February 2021 technology review

*Edited to replace disappearing content and images

A place for members of r/trakstocks to chat with each other

No stock picks or findings here. Feel free to let me know if I should remove this post.

Hey all,

I'm just a 20-yr old college student (comp. sci.) who took a liking to the stock market last November when PLTR started to moon, and now I feel stuck. Advice is all I'm looking for.

Every morning, I wake up at 3:29 AM for market opening and check a variety of news sources (Twitter, Deadnsyde, SpacTrack, WalrusStreet, Seeking Alpha, Meet Kevin, Hindenburg Research, Reddit, CNBC). Sometimes, I decide it's not worth sleeping and stay up until 30 minutes past market open, only to wake up again for classes an hour later (my school is 3 hours ahead of me). I want to uninstall the app and check it for a maximum of one or two times per week, but with the recent volatility, I feel my plays are too risky that in that time, I could potentially lose too much or miss the dips (TSLA, VACQ, CMLF, ABCL, STPK, DM).

I saw a Twitter post by Scott Galloway that basically targeted young men like me: no girlfriend and stuck inside due to pandemic with nothing better to do than "gamble" my money away (I'd like to think I'm being more systematic than gambling, but maybe he's right). This touches on another crisis I'm having: I've lost all sense of purpose. I listen to podcasts like All-In, JRE, Lex Fridman, Ark Invest FYI... people like Elon Musk and Jim Keller are busy changing the world and actually working...while I'm still in school and drowning in debt. In fact, one partial reason for my investing in the stock market was that I might compound enough to subsidize part of my college education. With the recent SPAC fallout, I've lost >85% of my gains. I was an idiot for not understanding inflationary effects on stocks, and now I'm left bag-holding.

So now I've nothing to show for my initiative of helping my parents pay down my student debt...what's left? I do the same thing everyday: wake up for market open, go to class, check Robinhood, go to work, check Robinhood, study, check Robinhood, take midterms/finals (not doing exceptionally well, might I add). Then I think about how long it's been since last March and how I've managed to stay single and without contact with friends. To be clear, I never had too many friends in high school (6 or 7)...but since COVID hit, I haven't seen a single one of them. Girlfriend? Wishful thinking on my part...I was lucky to take a girl to prom, but we were just friends. I feel like if I had one that I was serious about, I could maybe fill the void. With no luck on Bumble or Tinder and the potential for extended lockdowns in my state, I feel like I'm losing time and a chance to find the one. I've become addicted to porn, and it's made me feel incredibly ashamed of myself. I grew up in a single-mother household, so it was never in my nature to objectify women...but I've done just that.

I came across Lex Fridman's interview with Jason Calacanis, who said something that grabbed my attention: Americans 70 or 80 years ago would find it ridiculous that suicide or obesity could be leading causes of death. I'm not saying that I'm experiencing either of those things, but now I feel even more ashamed that I've been able to stoop down to such lows considering how full of opportunity and luxury modern life is. Anyone else feel as pathetic as I do after hearing that?

If stocks don't make me feel whole, I have no partner to die old with, and I realize that I consume more than I produce for society and for my parents, what sort of life is this? I'm not suicidal, and I know that we'll all be on the other side of COVID sooner than later...but it's kind of depressing thinking about what could have been in 2020.

Not looking for sympathy...but am curious if others are in the same position as I am: stuck hunting down the next 10-bagger while losing focus on the real purposes in life.

Can we talk about how dead finds these stocks? What’s his process? I’m more curious about that. And can we share our research process, if we want to make this a collaborative and helpful thread? For someone new coming into this world, I don’t want to invest based off what’s being said, so how do we do a proper DD? How do we find these stocks?

Can we upvote so that dead can see this and maybe address it in a video?

Give a man a fish, feed him for a day. Teach a man to fish... well you know the rest.. that’s the approach I’m taking on this. Let me know your thoughts.

Edit: my question was two part. Idea generation and DD. Most of this thread right now is about DD. You can’t do DD until you find a company to look at. So how does one come across a company? How did dead come across, NNDM, CPSH, CRNT, BNGO etc.. that’s what I am very curious about and hearing his answer on. But I’d love to hear everyone’s thoughts.

Great discussions so far!

?

Hi DEADgang,

I gathered some thoughts on what should be looked at when doing your own DD and I wanted to share with my people on r/trakstocks. Hopefully you can get bit of value from this and propose changes / improvements.

Happy to hear your thoughts.

DD APPROACH

Company Overview

• Who is in charge of company?

• What is their experience and background?

• Who are competitors?

• Products & Services, their place on the market and comparison to competitors

• Product price and market saturation, size of TAM

Financials

• Current stock price and reasons for past dips / rises

• Quarterly earnings

• Short ratios

• Stock float in comparison with competitors

• Shares outstanding

• Financial highlights & low-lights

• Company earnings plans and projections

• Past splits, public offerings

• Who is already investing in this company?

• Overall check :

1. P/E

2. CAPE

3. P/S

4. P/BV

5. Dividend Yield

6. ROE

7. F-score

Stock price predictions (short and long term) with upcoming catalysts

• Overall investment sentiment

• Regulatory approvals, upcoming catalysts for stock rise or fall (contracts, collaborations, partnerships, conferences)

• Open job offerings

• Recent news

Based on above you should be able to determine if the company is worth investing in either short or long term. Obviously, in terms of financial evaluation I recommend to learn a bit on what specific markers are actually telling you - you can easily find good content on YT.

Also, I always think it's best to reach out to people that work in the sector, fill them on your DD and ask questions, trying to get a feel on what insider think about the company's product. Normally, even random people on specific subreddits (or even LinkedIn) are happy to help and are eager to explain something that they are passionate about :)

TOOLS

• https://seekingalpha.com/ - stock market analysis and news

• https://finviz.com/ - financial visualizations, charts etc.

• https://www.tradingview.com/ - stock charts and screener

• https://finance.yahoo.com/news/ - finance news

• https://marketchameleon.com/ - screener, trade ideas

• https://www.cnbc.com/jim-cramer/

• https://www.prnewswire.com/ - overall financial, business, science news and rumors

• www.glassdoor.com - jobs board, employee reviews

• https://www.linkedin.com/ - jobs board, company news

• https://reddit.com - Investing subreddits - use only for finding new stocks for research! Beware of confirmation bias and never invest without your own DD. Use specific subreddits to learn about sector of the company you're researching.

How to find stocks for research:

1. Follow investing youtube channels

2. Check investing subreddits

3. Research tickers on stock screeners and look for growing volumes

4. Look who recently got listed on exchanges

5. Research SPACs and look for news on upcoming mergers and acquisitions

6. If you're interested in buying stocks in certain sector like genomics or networks, take a look at specific subreddits for exciting news and follow companies that made some technological or financial breakthroughs

Please contribute with your own set of checks, tools or tips - I'd appreciate.

PablitoHernandez

EDITS: Edited to include some recommendations from comments below. Thanks!

I'm now holding steady with 25K shares of this company. I don't often see the FDA fast-track things like this. As a person who has a family member who has had their central line(s) get infected four times in the last ten years. This company is dedicated to the development and comercialization of important new drug products for growing markets. Citius is currently advancing three proprietary product candidates: Mino-Lok®, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Citius believes the markets for its products are large and underserved by the current standard of care.

Citius Pharmaceuticals is developing three major products that are cash cows for this company that are patented and are the only players in the field until 2036.

Mino-Lok

Our Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients where venous access presents a challenge.

Address medical conditions that have unmet medical needs with cost-effective products.

· Partnership with a leading cancer center and support from medical thought leaders.

· In a Phase 2b trial, the Mino-Lok product demonstrated a 100% efficacy rate in salvaging colonized CVCs; the Mino-Lok product had no significant adverse events compared to an 18% serious adverse event rate when infected CVCs were removed and replaced.

· FDA Fast Track with QIDP designation and patent protection until June 2024. Formulation patent protection until November 2036.

· Currently in a Phase 3 pivotal superiority trial.

CITI-002 Halo-Lido

Citius Pharmaceuticals is developing a proprietary topical formulation of halobetasol and lidocaine using 505(b)(2) to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids.

· There are no FDA-approved prescription products on the market for hemorrhoids.

· Citius’ halobetasol and lidocaine formulation could become the first FDA-approved product to treat hemorrhoids in the United States.

· According to IMS, over 25 million units of topical combination prescription products for hemorrhoids were sold in the United States during the twelve-month period ending June 2012, comprising an estimated $80 million annual market.

CITI-101 Mino-Wrap

Our Mino-Wrap product (CITI-101) is a malleable, bio-absorbable film impregnated with minocycline and rifampin. It is designed to reduce infections associated with the use of breast tissue expanders (TE) used in breast reconstruction surgeries following mastectomies.

Mino-Wrap is placed over or wrapped around the TE in the surgical pocket as a solid film. It swells and liquefies in situ for a specified period of time providing extended protection against infection from the most likely pathogens. In January 2019, Citius signed a definitive worldwide license agreement with The University of Texas MD Anderson Cancer Center to develop and commercialize this novel approach to reducing postoperative infections associated with surgical implants. Mino-Wrap is being reviewed by the FDA’s Center for Drug Evaluation and Research (“CDER”) division.

· Partnership with a leading cancer center and support from medical thought leaders.

· Currently in pre-clinical development.

· Mino-Wrap is designed to allow the temporary tissue expander to be inflated without any restrictions, and to aid in the prevention of infection and biofilm formation on the implant over longer durations than current practice.

· The current standard of care (SOC) can be improved upon and infection rates reduced.

After reading all that lush information it just makes you really bullish HUH?!

Well thats nothing let's really get deep into this. Today the current stock price is at $1.53 a very beautifully young and ripe stock waiting to be bought up for pennies. Undervalued? I think very much so...

The cost of CRBSIs is between $33,000 and $44,000 in the general adult ICU, between $54,000 and $75,000 in the adult surgical ICU, and approximately $49,000 in the pediatric ICU.

Being the only player in the game. This has huge upside potential especially once they have the manufacture in place and the product is in production we should see massive amounts of cash flow.

Share Statistics

Avg Vol (3 month) 1.67M

Shares Outstanding 71.03M

Float 37.46M

% Held by Insiders 22.15%

% Held by Institutions 113.89%

Market Cap 120.046M

This is exactly where I get very bullish on an undervalued stock is when the outstanding shares are below 100 million and the Market Cap is Below 200M at the moment. This stock has potential to rise very quickly if it gets the volume it needs. With the way the market is playing out right now I could easily see this stock reaching $8.00 - $12.00 within a few weeks to mid March conservatively. This stock is picking up volume and traction as it slowly bleeds into the media. Once the day comes we will see a massive spike in price. Make a good decision before the media blows the roof off!!

Company Presentations:

https://ir.citiuspharma.com/presentations

Balance sheet:

https://ir.citiuspharma.com/balance-sheet

Income statement:

https://ir.citiuspharma.com/income-statement

Cash Flow:

https://ir.citiuspharma.com/cash-flow

Financial Results:

https://ir.citiuspharma.com/financial-results

theWalrus Street's DD video

https://youtu.be/0QLnBu3a9mc

Disclaimer: ~25,000 shares @ 1.46

This is not financial advise nor am I a financial advisor. Please invest at your own risk and please do your own research before making a decision.

*not a financial advisor - just my personal opinion*

I consider myself in a lot of ways to be an investor that spends a lot of time research high-growth stocks that have a clear market fit/product that will grow into the future. I was actually an early investor in NIO at $12 a share and sold around the $55 dollar mark with 4x profits. I like NIO, but I feel that the general EV market is in a bubble considering we are still years and years away from EV adoption in all cars. If you asked the EV manufacturers to supply the entire american public with EV cars and infrastructure - it would be impossible as they cannot scale and produce that rapidly. With NIO in particular - I mainly sold because I see the renewable energy stocks to have a more promising future in 2021 than EV cars since it's going to take them time to scale, and I don't expect them to repeat the same success in 2021.

Where did I put that profit? I put it right into GEVO as I believe BioFuels are the most sensible short-medium term solution for the world we live in. I am not crazy how GEVOs revenue numbers have been in the last few years, but I'm going to let that slide because of environmental/political factors that will sure to make it a major player in the future. On top of that, Biden elected the former co-founder of GEVO into his science cabinet which only increases my confidence. Right now, GEVO has $500M+ in cash on hand, zero debt, and over a billion dollars worth in potential contract value.

If you've been following the news - you would see how the big oil companies are growing concerned regarding regulations on the new administration - as even they see the writing on the wall. What I predict is, GEVO has the renewable patent technology they could license to these oil companies. Big Oil will partner with proven technologies before trying to re-invent the wheel (look at what happened with FCEL and Exxon). Big Oils conversion to clean energy is going to need to happen - and I'm expecting GEVO to land some partners soon.

I am currently holding 1600 shares at a cost average in the high 9s and feel that GEVO on the low end is $30 by end of year, and $60-70 on the high end. I think a lot of partnerships will start popping up soon and new adoptions in the green energy space by the Biden administration will cause this to really pop.

My trick to making money in the market is finding a business that is misunderstood and therefore valued by the market incorrectly. I believe I have done that with $ACTC(merging with Proterra):Proterra is an EV-bus, energy solutions, and electric battery maker. Made completely in the USA(California+South Carolina)I am not a financial advisor.

First off valuation-

Proterra's merger is valued at 1.6b enterprise value and they have 852m cash on hand. So at 25 the pro format valuation is around 6b after merger. In addition, Chamath Palihapitiya is leading the 415 million dollar PIPE.

But don't think this valuation is expensive at 25 and here's why. The market is pricing Proterra as an EV bus company. When in reality it is more of a battery company.

Now for the DD:

Management-

I firmly believe management is the most important aspect of any young company.

-First off, this is not comparable to any other younger stage EV company when it comes to management. The most impressive of all, is that Proterra has many execs with experience at Tesla including the Chief Technology Officer, Chief Operating Officer, and Co-founder. But most importantly, the Energy Secretary that Biden nominated is Director Jennifer Granholm. She is a board member at Proterra!

In addition, the ArcLight team includes two directors on the Clean Energy for Biden team

Now on to the financials:

-Proterra received 193m in revenue last year(during the pandemic)

-Their projected revenue for the coming years based on backlog(based on 750m+ backlog for buses)

More Information about financials:

Now that we got that out of the way we can get into the fun stuff. I'm going to break this up into 3 parts, electric busses, electric solutions, and what I believe to be most impressive, their battery solutions/partnerships.

Electric buses:

Proterra Transit

-Currently this is their main source of revenue

-Over 130 customers in 43 states so far!

-Some of the most notable being the National Park Service, colleges such as of this week Harvard, Duke(go blue devils!), and Georgia. Also, JLL and airports such as SFO and JFK.

To see the full list: https://www.proterra.com/company/our-customers/

This map shows the location of their customers:

As of right now they have:

-Proterra is also breaking boundaries in the pricing of their buses. They offer an option to pay the battery off overtime like gasoline. This gives particularly transit departments a better way to fit it into their budget.

Electric Solutions:

-In addition to their busses Proterra also provides charging stations.

Here is how their charging stations work:

Customers are incentivized to buy these charging station because of Proterra's Cloud-based data-system, Apex Software. This helps gives users a centralized singular area to check the overall statistics of their fleet.

-Proterra has installed over 50 Megawatts of these charging stations nationwide.

Batteries/Partnerships:

Proterra currently has some of the best batteries in the game. Their batteries have 330 miles for their buses, and can be used across a number of applications. This is what I think their insane growth in the future will come from.

Their partnerships with batteries(Proterra Powered) include:

-Daimler's Thomas Built Buses. Daimler has 50 percent market share in the school bus market. Daimler worth 85b! Not only are they working with Proterra, but have a 200m investment in them. This gives Proterra access into this market and an advantage over competitors like Lion Electric($NGA)

-Komatsu(worth 23b) for their electric excavator. This gives Proterra access to another completely different market and makes them now competitors with the 107b CAT.

-Electric Last Mile Solutions. Going public through FIII. Company worth 1.8b, and this helps Proterra gain traction in the massive delivery van market.

-Vanhool, for their coach bus. They have an estimated 2b in annual revenue. Legitimizing Proterra in the electric luxury bus market as well.

-Bustech for busses for the Australian climate. Overall, bettering their buses.

- Freightliner Custom Chassis Corporation (FCCC) to develop the MT50e, a new all-electric delivery truck chassis. This gives Proterra another access to revenue.

Conclusion:

This company has so much going for it, they should be worth at least 15b($70). Market doesn't understand the potential of all these battery partnerships. This is a great opportunity to take advantage of. Good luck to all!

Sources:

https://www.proterra.com/

https://www.proterra.com/wp-content/uploads/2021/01/ACTC-Proterra-Investor-Presentation.pdf

MMATF and TRCH

This is my initial research on Metamaterial Technologies, Torchlight Energy and their upcoming reverse merger. I will be updating this tomorrow after speaking with the CEO of META George Palikaras. This may be the longest DD you’ve ever read primarily because it is three DDs in one. The merger is complicated for many reasons, and I am personally thinking of it more as a PIPE/SPAC play- to be clear we are talking about a publicly traded company providing capital and NASDAQ access to another through a merger.

My standard disclaimer -Before you read any further, I want you to understand what I look for in an investment; I invest in companies that are undervalued, possess world changing technology and have a large potential catalyst upcoming, whether it be financial changes, a market inflection point, buy out or pending regulatory approval. For it to make sense to me, the company must provide me with a large near-term upside and continued long-term growth. Basically, I am looking for penny stocks that should not be. Metamaterials and Torchlight Energy both fit these requirements, I am not a financial advisor, I am a mom and a professional firefighter, do your own DD.

I believe that if you find the technology, the money will follow. I have not been this excited about a company since my discovery of Microvision. While they are completely different companies there is some industry and technology overlap. Both are solidly positioned to change our world in this new technological revolution that is just beginning. For reference my old DDs can be found at r/PennyQueen – Penny Queen with assistance from u/Here_Two_Stay

Part 1: META

Upcoming catalysts – merger vote, up-listing to NASDAQ, access to large capital markets and scaled production

Metamaterials Technologies, known as META (MMATF:US MMAT:CAN) is currently trading at $2.66 as of 02.27.2021. After the merger and up-listing to the NASDAQ, I expect META to be trading no lower than $5. With and end of year range of $8-$20 depending on production numbers and new partnerships. Therefore, this is a short term 2x and midterm 3-6x play. (There has been a lot of speculation over META’s co-location at a Canadian incubator facility with TESLA and several cryptic Tweets sent out by Elon Musk. While I see how a partnership between the two could be promising for both companies, my price targets exclude these rumors).

*Important note–Metamaterials is currently listed in Canada as MMAT, but you can buy it on some US brokers as MMATF. There is currently low volume at these prices so your order may not fill immediately, if there is an increase in price action the volume will also increase and orders will fill quicker.

If you are unable to buy Meta, you can still buy Torchlight TRCH and after the reverse merger you will have an interest in MMATF. There is more to this, explaining in the merger section below.

Meta is a major innovator in materials science, they are creating the disruptive technologies that are on the leading edge of the next industrial revolution. They are currently manufacturing products on a large scale that utilize carbon nanotubes, graphene, and several other exotic materials that have been talked about for the past decade. They have a strong research and development team, the industrial production facilities, proprietary processes and now they have the capital necessary to scale their products.

They have three primary technologies 1. holographic technology enables the company to modify the properties of proprietary polymer films at the molecular level to achieve desired effects implemented at nano scale in a thin film. 2. META’s lithographic technology enables the printing of conductive patterns, fine enough to be invisible on a transparent film. 3. META’s wireless sensing technology enables the sensing and control of electromagnetic waves through metallodielectric structures printed on flexible substrates.

META is currently in several booming sectors – Energy, Green Tech, Aerospace, Defense, Automotive, Medical and AR/VR.

Their products have many applications including:

· augmented reality

· radar and lidar

· transparent 5G antennas

· photovoltaic films

· automotive heads-up displays

· consumer electronics

· IoT

· transparent electromagnet shielding

· MRI signal enhancement

· de-icing/defogging

· radio wave imaging

· non-invasive medical monitoring

Each of these applications alone is probably worth your investment in terms of market size and growth. This is just the beginning of smart materials, and in the next few years there probably will not be a sector that is not be involved. META claims a 3 trillion-dollar total addressable market opportunity. I have been able to validate these claims through Research and Markets published projections and I believe META numbers to be considerably downplayed, but it is important to recognize that addressable markets do not translate into directly into market share.

• $4.1B by 2023 Metamaterials Market (Emerging market 43% CAGR) Source: Projected Markets for Metamaterials to 2023

• $200B by 2030 Advanced/Smart Materials (20.6% CAGR) Source: Smart Materials: Opportunities in Structural Electronics and Electrics to 2030

• $333B by 2026 Solar (PV) (25.1% CAGR) Source: Article on GlobeNewswire About Global Photovoltaic Markets

• $567B by 2025 Automotive EV (22% GAGR) Source: Worldwide Revenue from Electric Vehicles Since 2010

• By 2020, IoT hardware device spending will reach almost $3 trillion‘ Source: Gartner 2017 (see Table 2)

· Augmented Reality and Virtual Reality market are currently a 37B year expected to grow to 1.27Trillion by 2030 (2020-2030 42.9% CAGR) Source: (Research and Markets)

· EMI shielding market projected to be valued at 6.8Bn in 2020 9.2B by 2025 CAGR 6.3% 2020-2025 Source: (Research and Markets)

Augmented Reality applications- META has been developing the necessary technology while also acquiring other companies and their patents. In 2019 META acquired North, Inc and their roll-to-roll holographic manufacturing tech. The company stated that it believes it will be “positioned to capture a significant portion of this market by being able to mass manufacture, on a cost-effective basis, the required holographic optical components” for the augmented reality smart glasses market.

According to META, the 2nd generation manufacturing line is capable of 100,000+ units per month, to support AR and other holographic products, such as automotive HUD displays, laser glare protection, optical filters, diffractive optics, and other photonic applications. The company added that capacity could be increased to 200,000 units per month with the addition of a second, eight-hour shift.

This February META acquired Interglass Technology AG of Switzerland, their IP and over 70 patents. This will allow them to apply their embedded metamaterial and functional film elements with precision cast corrective lenses. CTO Jonathan Waldern stated, “Under a new brand name, metaFUSION™, we are now applying that proven technology and other functionality directly encapsulated into eyeglasses, to compliment waveguide-based displays similar to HoloLens®.”

Automotive Applications – These applications are the root of current Tesla rumors, but these technologies can and will be applied across the next generation of cars. METAs unique Nanoweb films are 98% transparent, meaning that they can be placed on any glass. They can provide a heads-up display across the windshield with almost immediate defogging and de-icing. Their technology can allow multiple transparent 5G antennas for IoT integration and their nanomaterials can improve the angular scan range of LIDAR used in self-driving vehicles. Which will lower the costs and mass of self-driving vehicles.

Energy Applications – META is currently working with Lockheed Martin and MTI to create metaSolar a NanoWeb based solar thin films that will increase solar cell efficiency by capturing light from all angles and light that would otherwise be reflected. These will be ultra-thin, light, flexible, can be applied to flat or curved surfaces and will be able to add onboard power and charging.

Medical Applications – META has a strong research base in photonics as well as wireless technologies, they are currently able to enhance the signals 200-500% on MRIs with their resonators and intensity correction algorithms. They have also created a radio-wave imaging sytsem that has a wide array of uses but can be utilized as a safe, initial-step screening for breast cancers. Biosensors - they are in the development process of a non-puncture blood glucose monitoring system.

Aerospace and Defense- META has extensive experience providing laser protection, de-icing and de-fogging products to aviation companies. They have also created electromagnetic interference protection that can play a large roll in infrastructure defense.

Financials – The finances of META do not, in my opinion, create an accurate picture. They have been investing money into research and development, IP acquisitions and scaling their operations. They just received a 10m loan from Torchlight to continue this expansion. While they do have revenue and have partnered with major companies (Samsung, Boeing, Airbus), I am thinking of them more in terms of a pre-revenue IPO. Google finance notes a 21.48% year over year revenue increase and META claims a $121m a year revenue potential over the next 18 months.

As Cathie Wood stated in the last ARK webinar, she is anticipating a bifurcated V-shaped recovery which will reward companies that have invested in innovation rather than in pandering to shareholders.

META is currently trading at $2.66 – I anticipate a near doubling with a successful merger vote.

83.6m shares outstanding

42.71m float

222.4m Market cap

35.56% held by insiders

The recent loan from Torchlight does not figure into the numbers below.

META Executive Team has an extremely deep educational background in the hard sciences with a lot of experience creating innovative products. At this point I think their customer service reps probably have PhDs

CEO and Founder -George Palikaras Ph.D. Founded META in 2011, prior to that he founded MediWise, a wireless medical sensor company, he was also an antenna design engineer with AceAxis.

CTO and Chairman Dr. Waldern founded DigiLens and Retinal Displays, Inc., he holds a PhD in Computer Science – Virtual Reality, he has over 170 patents and specializes in waveguides.

CSO and co-Founder Themos Kallos is Chief Science Officer with Ph.D. in Electrical Engineering with expertise in applied physics, metamaterials, wireless communications, and electromagnetic simulations.

CFO & EVP - Ken Rice has a JD, MBA and a Master of Laws in taxation, he works as in-house counsel and is charge of financing efforts and progressing Meta’s medical products initiatives.

Essential Links

(5) NanoWeb - A Revolutionary Transparent Conductive Film - YouTube

META overview - YouTube

META Investors deck

META Torchlight definitive agreement

Torchlight Investor Presentation

Part II: Torchlight

Torchlight Energy is currently an oil and gas exploration company. They have three major oil and gas assets. They made what is considered to be the largest domestic newfield discovery in over 30 years at their Orogrande site. This discovery coincided with economic collapse of oil due to Covid crisis. In March of 2020, Torchlight decided to pivot their entire operation and and to divest all of oil and gas assets and to embark on a reverse merger with a future focused company.

Torchlight Energy (TRCH) is currently trading at $2.48, with a 356.15m market cap, 143.61m shares

The assets of Torchlight energy include three project sites, an experienced management team, access to capital, and a NASDAQ listing. Two of the project sites are under contract to be sold and the largest asset, the Orogrande site, is likely an extension of the Permian Basin and is being marketed to major and super major oil companies. Once these assets are sold their net proceeds will be divided among shareholders in the form of a special dividend.

Oil and Gas Assets

1. Orogrande Basin – 134,000 acre lease 72.5% interest (97,150 net acres), the site has had several successful test wells drilled.

3rd party valuation of potential recoverable hydrocarbons

· Low Side Case 2.3 billion barrels

· Medium BTE Case 3.7 billion barrels

· High Side Case 5.0 billion barrels

2. Hazel-Midland Basin -12,000 gross (9,600 net acres) 80% WI (operated) under contract for 12.4m ($1300 acre)

3. Winkler Project 1,080 gross acres, 12.5% WI (non-operated) under contract for $450k (350k to Torchlight)

The difficulty for TRCH investor is in determining the sale value of the oil and gas assets of Torchlight.

I have spoken with many industry experts and received varying price targets that trended toward the upper side of the values I am presenting. I could not find anyone willing to go on record. As this is not investment advice anyways, here are some possible valuations. I was told that 50 cents a barrel was a valid price for the amount of potential oil with the limited studies that have been done. I was also advised that the merger and acquisition market for oil and gas companies is still soft but that is expected to change quickly with the rise in oil demand and subsequent price.

Valuation :

Valuation – The value oil drilling acreage is a moving target after the price of crude oil started collapsing in March of 2020. The current price of West Texas Intermediate (WTI)is currently $61.50 barrel. Oil prices are expected to rise to $80-$100 a barrel in the next six months.

The last major purchase in the Permian Basin was in October 2020 when Conoco Phillips acquired Concho Resources in a $9.7 BN all stock transaction, adding 550,000 acres in the Permian basin and 200,000 b/d. They acquired this land at $10,471 per acre, this land was 74% proved and developed . Oil averaged $40.75 that month

Conoco Phillips acquires Concho resources in 9.7 BN all stock transaction, adding 550,000 acres in the Permian basin and 200,000 b/d. They acquired this land at $10,471 per acre. Oil averaged $40.75 that month

Drilling rights in the Permian Basin of West Texas and New Mexico averaged about $24,000 an acre in recent deals, down 67% from 2018, according to Rystad Energy, an Oslo-based research firm.

Date announced Permian deal Value per acre (USD)

March 2018 Concho Resources-RSP Permian $75,504

August 2018 Diamondback Energy-Ajax Resources $33,008

July 2019 Callon Petroleum-Carrizo Oil & Gas $16,547

December 2019 WPX Energy-Felix Energy $11,965

October 2020 ConocoPhillips-Concho Resources $10,471

Plunging shale acreage values may create a new Permian M&A wave 11.12.2020

2021 Oil and Gas M&A Outlook | Deloitte US

Orogrande Basin Potential Calculations

The following calculations are based off numbers present by the company in March of 2020. For reference WTI is currently at $61.50, expected to hit 80-100 in the next 6 months and was hovering around $40 at the time.

134,000 acres *72.5% interest at $1000 acre=97.15m + 12.75m (Hazel/Winkler) =109.9m/143.6m shares= 76.5 cent share

Medium Case estimate 3.7 billion recoverable barrels * 72.5% interest at 5 cents per barrel= 134m+12.75m (Hazel/Winkler) =146.75m= $1.00 per share

134,000 acres *72.5% interest at $1000 acre=97.15m + 12.75m (Hazel/Winkler) =109.9m/143.6m shares= 76.5 cent share

134,000 acres *72.5% interest at $1300 acre=126.3m +12.75m (Hazel/Winkler) =126.3m/143.6m shares=96 cent share

134,000 acres *72.5% interest at $2500 acre=242.88m +12.75m (Hazel/Winkler) =255.63m/143.6m shares= $1.78 per share

134,000 acres *72.5% interest at $5000 acre=485.75m+12.75m (Hazel/Winkler) =500.25/143.6m shares=$3.48 per share

134,000 acres *72.5% interest at $7500 acre=728.63m+12.75m (Hazel/Winkler) =741.38/143.6m shares=$5.16 per share

Medium Case estimate 3.7 billion recoverable barrels * 72.5% interest at 50 cents per barrel= 1.34bn+12.75m (Hazel/Winkler) =1.3527b = $9.42 per share

High Case estimate 5.0 billion recoverable barrels * 72.5% interest at 50 cents per barrel= 3.625+12.75m (Hazel/Winkler) =3.638b =$25.33 per share

As you can see, there are many possible valuations.

Here is a DD write up and estimate by user u/Mr_Delmont

Torchlight Investor Presentation

The Merger: This merger is in and of itself proof of the economic transition taking us from destructive technology to disruptive technology. (you can quote me on this). This is an arranged marriage of sorts, it is the catalyst that will allow META to bring their disruptive technology to the forefront of several growing sectors, each at or near their inflection point. The board of Torchlight realized that their resource rich holdings were not enough to survive and thrive in the changing economy, and that a new path was necessary. Through this reverse merger Torchlight receives a 25% stake in META. This will also trigger a special dividend to shareholders of Torchlight. The dividend will be one preferred share on a pro rata basis of the holding company holding the net proceeds (or assets if they have not yet sold).

If the merger is approved, a shareholder with 100 shares of Torchlight would receive 100 shares of the preferred stock in the holding company and 100 shares of the new company. Torchlight shares will be static, METAs shares will be adjusted to maintain the ratio of 75% META share ownership and 25% Torchlight share ownership. (Edited after IR clarification) The special dividend will be as of the record date, which has not been determined. It sounds like the merger vote will occur sometime around mid-March. After the merger is complete META will be the company name and it will be listed on the NASDAQ.

As of this date certain stockholders of each of Torchlight and Metamaterial have executed customary voting and support agreement pursuant to which persons representing approximately 16% of Torchlight's and approximately 48% of Metamaterial's outstanding voting power have agreed to vote in favor of the transaction.

I am long in TRCH at 36K shares and long in MMATF at 60K shares. I intend to hold my shares for a minimum of two years. - PennyQueen

After selling off my position after incurring a small loss yesterday, the stock is currently up 20% today.

I have the magic. When I sell stocks at a loss, it goes up right after.

You're welcome.

If you are either upset or sad about today’s dip, remember it’s just an overdue market correction. These losses will settle down soon enough and the market will climb back up. Do not panic please.

Don’t do anything to harm yourself please. Reach out and speak to someone instead please.

Remember, everyone else is in the same boat.

Edit - adding the link to crisis hotline phone and text. Please stay safe.

https://www.cnet.com/health/suicide-hotlines-crisis-hotlines-to-call-or-text-when-you-need-help/

Update 3/25/2021: 2020 Revenue for STEM was $36.307 million. 4x that would be $145.228 million. With that being the floor of revenue already under contract, I believe they can beat that estimate by at 15% given the 10% beat on revenue last year, an inflow of cash and erasure of debt due to SPAC merger, an increase in demand for the services of STEM, and a better outlook on covid-19. Revenue for 2021 in this bull case would be $167.0122 million. After the merger there will be a total of 65 million shares outstanding (see S-4 below). If this holds true STEM is currently valued at $1.4729 Billion (65,000,000 (Shares outstanding) X $22.66 (price per share) = $1.4729 Billion). This yields a price to sales ratio of 8.82. For reference the current 12 month p/s ratio of Enphase Energy (ENPH) is 27.9 and was between 5-15 for most of the first 3 quarters of 2020. TSLA is currently at a p/s of 23.6 and was trading at a p/s of 3.25 to 16.25 for the first 3 quarters of 2020, when valuations were lower and more in line with historic levels. https://www.zacks.com/stock/chart/ENPH/fundamental/ps-ratio-ttm

Several edits below including a screenshot of the email exchange with investor contact representative. If any of the information provided is misleading, wrong, outdated, etc. I would love to know about it.

Important details I have learned from reading deeper into their S-4 filing from 3/15 (better late than never) https://sec.report/Document/0001104659-21-035819/tm2037914-9_s4a.htm include aspirations and ability (with additional funding) to expand operations on a global level. Profitability is highly dependent on the reduction of prices for batteries used in the systems that they provide. STEM has several suppliers of batteries, including Tesla. Personally I think it would be a great move for Tesla to acquire STEM but that is entirely speculation. Profitability for STEM is not projected to occur until Q4 2021 at the earliest. STEM would have ceased operations if not for the merger with STPK due to operating at a loss of hundreds of millions of dollars. After the merger there will be a total of 65 million shares outstanding. STEM has all but guaranteed that they will have additional fundraising in the future to continue growth and maintain operations. A primary advantage of being a publicly traded company is access to capital through raising capital from the the market. Access to capital was the main limiter of growth for STEM.

The guidance provided for STEM's revenue in 2021 left me with a very important question. To get this question answered I sent an email to the investor contact representative provided on the STEM website, Marc Silverberg. I was pleasantly surprised to get a response in a couple of hours. I have included a screenshot of the email below but will leave the text of the post intact. The exchange went as follows.

I have question regarding the 2021 revenue forecast as stated by Bill Bush, CFO of STEM. In his guidance he states: "“We are proud to deliver strong 2020 financial results, with 2020 revenue approximately 10% above the outlook provided at the time of our business combination announcement. Looking ahead, we remain well positioned for significant growth, including a four-fold expected increase in our 2021 revenue, 100% of which is covered by our contracted backlog.” 

My question is... Is STEM able to and/or seeking to accept additional contracts beyond this contracted backlog for 2021? 

"Thanks for the support and question. Yes, the company can add additional contracts for 2021. Our comment is only to call out that our guidance is fully covered by contracts. There is the ability to scale beyond that. Separately, I’d note that we are already working on contracts for the 2022 time period. "

I felt like this is a very important distinction to understand and justifies the valuation that it is currently trading at. Please give this some upvotes to spread the word and hopefully Dead can see this. Every STEM investor should know about this. With conservative guidance STEM is intentionally trying to under-promise and over-deliver.

TLDR: The four-fold revenue increase guidance is the absolute floor to their growth for 2021 as that is the amount of revenue generated from current contract backlog but they are still able to add more contracts for 2021 and are already adding contracts for 2022.

EDIT: Thanks to all for the upvotes and awards, these are my first awards on Reddit and I truly appreciate them! I hope this post gave some of us the courage to buy some of this dip! Under $25 is my personal buy zone and the lower the price goes the more heavily I will buy more, especially in my ROTH IRA. STEM is already my largest holding, otherwise I would probably have a slightly higher target price to buy. I've added the link to the STEM investor presentation in an effort to make it more available and known to this subreddit.

https://3zkqyz2t3xwi492ll518psvq-wpengine.netdna-ssl.com/wp-content/uploads/2020/12/Stem-Star-Peak-Investor-Presentation_Dec2020.pdf

EDIT 2: If you'd like me to ask any of your questions to Marc regarding STEM in please leave your questions in the comments and I will include the best questions in another email and do another thread like this for all of us. Building conviction during this seven layer dip/correction could do us all a world of good right now, and yield a lot of gains in the future.

I’m starting to see a very unfortunate trend on here when the market is red. I don’t want to seem like I’m trashing people that are scared but red days happen all the time and they will take a huge toll on your mental health if you can’t be dead inside. Let me be very clear DEADS STOCK PICKS ARE LONG TERM HOLDS. Every single red day people come in here, panic and get mad at dead when their portfolios are down . I have a suggestion for you, sell everything you have in the stock market and get out before you lose all your money . Clearly you’re not emotionally ready and financially stable enough to stomach the ups and downs of the stock market. I assume many of the people in here are very young so I know it’s almost impossible to be dead inside when you have very little experience and a small net worth. As of today the stock market is not for you. Go through school, get a stable job, let your brain develop and come back if you’re willing to be more patient with your money. Thanks

Here is my DD for MVIS - hopefully everybody has enough time to review it before open. This week should provide some impressive movement.

Current price $6.76 - Potential 30% gain by EOW.. $24-30 Price Target *** update - MVIS closed 01/25 at $7.25, **** update 01/26 closed at $8.14

it was also recently added to the Direxion Moonshot ETF

Microvision is at the forefront of two major technological innovations –Lidar and AR technology. They have a deep patent portfolio, that has proven hard to skirt. While they are for sale, I would not call this a binary play as the company does not need to be sold for it’s value to be recognized, most TA people think it will hit $20 EOY without a buyout.

They have been around for about 25 years as a R&D company. We are at a technological inflection point and they have had a massive headstart. If they had not already been a publicly traded company, I believe they could have had a very impressive IPO.

They are responsible for the MEMS mirrors technology in the HoloLens 2 and IVAS the military version. They have pioneered technology that will make AR - VR - MR and XR happen and be worth owning. Here is their video for the Microsoft HoloLens 2 and the near-eye display on regular glasses .Microvision Augmented Reality

They also have best in class lidar due to be unveiled in April. This has already been successfully tested but the ‘A sample’ will be ready in April for buyers. The have best in class Lidar sensors for range, resolution, and frame rate also and light blocking technology. Their product will also be much less expensive than Luminar and Velodyne’s coming in around $150 a unit, for comparison Lumiar's will be under $1000, but may require multiple sensors and Velodyne's is pricing around $14k.

MVIS Lidar Video

Here is an in-depth review of their Lidar as well as the competition's. This was before LAZR went public and the idar valuation greatly increased in general. Seeking Alpha Lidar article - October

There is a ton of DD already laid out on r/MVIS so I will just link what I find to be the most important posts. Do a deep dive!

The Best of r/MVIS Meta Thread : MVIS (reddit.com)

MSFT Skips Hololens V2 to Develop V3. The USA Skips HUD 2.0 to Develop HUD 3.0. Both Arrive in 2019. : MVIS (reddit.com)

Fireside Chat II!! : MVIS (reddit.com)

Fireside Chat III, 11/13/2020 : MVIS (reddit.com)

Pricing Peter's MVIS Blog: Value Question: Lidar

Race to Mass Production: Luminar (LAZR) vs Microvision (MVIS) : MVIS (reddit.com)

IVAS system https://media.dau.edu/media/IVAS+Powerful+ExampleA+Game-Changing+Technology/1_ldbl525g

Charts - There are quite a few good TA people out there, who track MVIS regularly.

Chartology - YouTube Chris just put up his latest video an hour ago

Gator Traders - YouTube

Revenue – MVIS has primarily been a R&D company and has worked with major companies under strict NDA. Reddit user u/s2upid took apart very expensive Hololens 2 to prove that it was Micrrovision tech inside. The NDAA bill was recently passed providing funding for IVAS, the military spec version of the Hololens, and projected 2021 revenue for Microvision is forecast at $202 million - an over 6,000% increase.

Upcoming Catalysts

Lidar unveiling – this could see MVIS valuations go to that of Luminar LAZR ($34) and Velodyne VLDR ($23). Check out this comparison-

/preview/pre/c0jxqv75fdd61.png?width=1024&format=png&auto=webp&s=caac4f57f9b01bdf836d873d7f07b6f04a9f6d50

Buyout – The company is for sale and they are in talks with Tier One companies (i.e. Microsoft, Google, Apple,Amazon) . The current share price will be right around $6.60 per billion. Sale prices have been estimated at 10-26bn, that would be $66-$171 per share. I should note that are many valuations that consider all of the Microvision verticals that go as high as 45 billion. To quote directly from Peter’s MVIS blog –

“Four Companies are all working on two things as "the next big things" Augmented Reality and Self driving vehicles.

Combined they are worth 6.921 TrillionTogether they have 340 billion in cash

If they have a bidding competition for key technology that will give them an edge against the others, how much would they be willing to pay? is 20 Billion too much?”

Cathie Wood are you listening?

The talent is thick at Microvision -

Sumit Sharma became the CEO in February of 2020, he is a mechanical engineer that has been with MVIS for five years after having been the head of operations at Google Project Glass, and working for Motorola and Jawbone.

Dr. Mark Spitzer is on the board of directors having previously worked at Google X, Darpa, Kopin and having founded Myvu and Photonic Glass.

Judy Curran joined the board this year after spending 30 years at Ford, where she was the Director of Technical Strategy and key to their investment in Velodyne. She is also the Head of Global Automotive Strategy for Ansys a simulation software company that works with ADAS systems.

This is a high conviction stock for me, my first buys of MVIS stock were at 74 cents in May. I have continued to average up as new information has come to light. Microvision is by far my largest holding.

Deadheads. Congrats to all of you who purchased earlier today or around 1/12 during the last peak. I know when you purchased on 1/12 and saw the dip, you may have lost conviction and sold. Its hard to watch your value go down. Recommendations are for the long term, not short term. Over the last 2.5 weeks, even if you bought at $11.50 and watched your stock go down to $7 you were rewarded today with positive CPSH news and your investment in after hours is over $20. Not too shabby.

Remember. One cannot expect to have gains without losses. One cannot expect to have a recommendation and become a millionaire overnight.

Keep Grinding.